LEO PHARMA A/S: Financial statements 2025
CVR: 56759514
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
LEO PHARMA A/S (CVR 56759514) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. That is an increase of 8.4% compared with the year before. The profit margin was 18.4%. Equity in the 2025 report amounted to DKK 5,262,000,000. The solvency ratio was 25.7%. The company had 4,104 employees in the financial year.
- Revenue
- DKK 13,499,000,000
- Gross Profit
- DKK 8,240,000,000
- Profit/Loss
- DKK 2,489,000,000
- Equity
- DKK 5,262,000,000
- Total Assets
- DKK 20,445,000,000
- Employees
- 4,104
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 13.5 mia. | 8.2 mia. | 2.5 mia. | 5.3 mia. | 4104 |
| 2024 | 12.5 mia. | 7.5 mia. | -1.8 mia. | 2.7 mia. | 4184 |
| 2023 | 11.4 mia. | 7.1 mia. | -3.6 mia. | 4.5 mia. | 4490 |
| 2022 | 10.6 mia. EUR | 6 mia. EUR | -4.1 mia. EUR | 1.9 mia. EUR | 5252 |
| 2021 | 10 mia. | 6 mia. | -4.9 mia. | 5.5 mia. | - |
Official annual report
How creditworthy is LEO PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
LEO PHARMA A/S has won the tender "Amgros 2026 1.1203.a" issued by Amgros I/S worth 368,505,024 DKK.
LEO PHARMA A/S has won the tender "Amgros 2026 1.201.a" issued by Amgros I/S worth 286,787,957 DKK.
As of June 27, 2025, Rifat Ramicevic has joined the board of directors of LEO PHARMA A/S.
As of June 27, 2025, Kreesten Meldgaard Madsen has left the board of directors of LEO PHARMA A/S.
LEO PHARMA A/S has published its annual report for 2024. Revenue came to DKK 12,453,000,000, and the net result was DKK -1,776,000,000.
As of March 13, 2025, Poul Bo Kilund has joined the board of directors of LEO PHARMA A/S.
As of March 13, 2025, Sara Melissa Plov Hoff has left the board of directors of LEO PHARMA A/S.
As of March 5, 2025, Aino Anna Liisa Hurme has joined the board of directors of LEO PHARMA A/S.
As of March 5, 2025, Mark Philip Levick has joined the board of directors of LEO PHARMA A/S.
LEO PHARMA A/S has won the tender "Amgros 2025 1.350.a" issued by Amgros I/S worth 20,097,600,000 DKK.
About LEO PHARMA A/S
LEO PHARMA A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 1962. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB. The management consists of Christophe Dominique Luc Charles Bourdon and Philip Harald Eickhoff. The board consists of Jesper Brandgaard (chair), Paul Olivier Marie Navarre, Peter Helt Jacobsen Haahr and Aino Anna Liisa Hurme. The company is owned by LEO Holding A/S and Cidron Savanna 4 SARL. The company has 1,047 employees (2026). In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. Equity in the 2025 report amounted to DKK 5,262,000,000.